Meanwhile, already-intense competition is being fueled by a steady stream of studies of drug effectiveness
Trulicity (dulaglutide) is a prescription GLP-1 receptor agonist manufactured by Eli Lilly and approved to help manage type 2 diabetes
Common symptoms include headache, transient visual obscurations, and papilledema, which can lead to visual impairment or blindness if left untreated (1,2)
The growing number of overdose reports is drawing attention from regulators, medical providers, and attorneys, particularly as litigation involving weight loss drugs continues to expand nationwide
Purpose-built for physicians GLP-1s tied to lower risk for 10 types of cancer compared with insulin in type 2 diabetes Key takeaways: People with type 2 diabetes using a GLP-1 medication have a lower risk for most obesity-associated cancers than insulin users